Pfizer is paying BioNTech $225 million to kick off a new alliance aiming to develop a shingles vaccine based on the same messenger RNA technology that is the basis of the partners' Covid-19 vaccine. It's the third alliance between the two companies, but this time Pfizer brings something more to the table.
As healthcare organizations make progress on their way to the digital transformation of healthcare, choosing a health cloud vendor to support and enable that work should not be taken lightly.
A reportby Chilmark Research sponsored by Innovaccer offers a deep dive into what factors healthcare organizations should consider when evaluating health cloud vendor options.
INVEST 2022 is going to be held March 28-30 in at the Ritz Carlton hotel in Chicago. This year, we have four new categories reflecting the pandemic-reality and how it has reshaped healthcare. Apply now for a chance to pitch LIVE in front of VC judges. Please note that companies that have pitched in the last 12 months at a MedCity event are ineligible to apply. Selected finalists will be asked to register for the conference at a reduced rate.
By Dr. Danny Sands Wednesday, January 5, 2022 2:00 PM
The conversation about medication shouldn't end when the prescription is written. Physicians need to be accessible to patients to talk about how the medication is working for them, how often they are using it as prescribed, and what barriers they have to using it.
By Frank Vinluan Wednesday, January 5, 2022 12:47 PM
Pfizer is paying BioNTech $225 million to kick off a new alliance aiming to develop a shingles vaccine based on the same messenger RNA technology that is the basis of the partners' Covid-19 vaccine. It's the third alliance between the two companies, but this time Pfizer brings something more to the table.
By Johanna Kaufmann Wednesday, January 5, 2022 8:15 AM
Oncolytic viruses have the power to make the tumor more visible to the immune system and mark the area of attack. It is this anti-tumor immune activation that has the potential to induce long-term responses in patients.
No comments